Multi-omics prediction of graft problems after lung transplant
Official title: Multi-Omics-Based Prediction of Allograft Dysfunction After Lung Transplantation: A Prospective, Multicenter Cohort Study
Run by Shanghai Pulmonary Hospital, Shanghai, China · NCT07243964 · Data updated 2026-11-12
We will test whether repeated blood and lung-fluid multi-omics tests can spot early graft dysfunction in adults after lung transplantation.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 244 (estimated) |
| Sponsor | Shanghai Pulmonary Hospital, Shanghai, China Academic / other |
| Locations | 1 site (Shanghai) |
| Status | Recruiting |
| Started | November 1, 2025 |
| Main results expected | December 31, 2029 |
| Study ends | March 1, 2030 |
| Registry record updated | November 24, 2025 |
| Trial ID | NCT07243964 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) who have received single or double lung transplants, are clinically stable after surgery, can provide informed consent, and can attend scheduled follow-ups and sample collections.
✕Probably not a fit
Patients with active systemic infection or uncontrolled rejection, recent or untreated malignancy, pregnant or lactating women, those unable to comply with follow-up, or those enrolled in other immune‑impacting interventional trials may not receive benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, multicenter cohort that will collect blood and bronchoalveolar lavage fluid samples from lung transplant recipients over time. Researchers will apply cfDNA fragmentomics, peripheral blood single-cell RNA sequencing, and plasma proteomics and link these data to pulmonary function (FEV1) and clinical information. The goal is to build a multi-omics model to identify acute lung allograft dysfunction (ALAD) early and track progression toward chronic lung allograft dysfunction (CLAD). Longitudinal sampling and integration of multiple molecular layers distinguish this work from prior single-measurement or single-modality studies.
Why it matters
Potential benefit: If successful, this approach could detect graft injury earlier and help guide interventions to reduce acute and chronic rejection and preserve lung function.
How similar studies have gone: Prior single-modality studies using donor-derived cfDNA, single-cell transcriptomics, or proteomics have shown promise for detecting graft injury, but integrated longitudinal multi-omics prediction in lung transplant recipients is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Recipients aged ≥18 years undergoing single or double lung transplantation; 2. Postoperative recipients capable of understanding and providing written informed consent, and willing to comply with scheduled follow-ups and sample collections as required by the study; 3. Postoperative recipients clinically assessed as stable and eligible for routine follow-up and hematological examinations; 4. Recipients able to undergo dynamic pulmonary function monitoring during follow-up; 5. No planned participation in other interventional trials during the study period that may impact immune function or pulmonary function; 6. Retransplant patients will be considered as a new transplant event and may be included in the analysis. Exclusion Criteria: 1. History of active malignancy or presence of untreated malignancy within 5 years prior to transplantation; 2. Presence of active systemic infection or significant immune rejection; 3. Female patients who are pregnant or lactating; 4. Any other condition deemed by the investigator to be inappropriate for inclusion .
Where it's running
-
Shanghai Pulmonary Hospital
Shanghai, China Recruiting
Study contacts
- Principal investigator: Chang Chen, MD,PHD — Shanghai Pulmonary Hospital, Shanghai, China
- Study coordinator: Junqi Wu
- Email: wujunqi@tongji.edu.cn
- Phone: +8615618977421
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Electrical Impedance Tomography for Monitoring Lung Disease
This test tries to see if a painless, noninvasive imaging method called electrical impedance tomography (EIT) can track how air is distributed in the lungs of adults with lung diseases and healthy volunteers and how those results match standard spirometry.
-
Mosliciguat added to inhaled treprostinil for pulmonary hypertension from ILD
This trial tests whether adding inhaled mosliciguat to your inhaled treprostinil is safe and tolerable for people with pulmonary hypertension caused by interstitial lung disease.
-
Collecting lung sound recordings using Eko digital stethoscopes in clinic
This project will try to teach computer programs to recognize wheeze, crackles, rhonchi, stridor, rales, and cough from stethoscope recordings in adults with suspected or diagnosed lung conditions and in people with normal lungs.
-
Recording lung sounds with Eko digital stethoscopes in clinic
This project will test an AI that listens to lung sounds recorded with Eko digital stethoscopes to find abnormal sounds in people with or without lung disease.
-
Trop2- and EpCAM-targeted PET/CT to help distinguish non-small cell lung cancer
This project will test whether PET/CT scans that target Trop2 and EpCAM can show protein expression in tumors of people with suspected non-small cell lung cancer.
-
Early intervention strategies for lung cancer detection
This study is testing if using low-dose CT scans in community health centers can help find lung cancer earlier in people aged 40-75 who don't have a history of the disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.